Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)

BACKGROUND: The real-world EPIX study was conducted to gather information about the characteristics of patients with metastatic castration-resistant prostate cancer (mCRPC) who survived ≥2 years after treatment with the alpha-emitter radium-223. METHODS: This retrospective study of electronic health...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Daniel J., Agarwal, Neeraj, Sartor, Oliver, Sternberg, Cora N., Tombal, Bertrand, Saad, Fred, Miller, Kurt, Constantinovici, Niculae, Guo, Helen, Reeves, John, Jiao, XiaoLong, Sandström, Per, Verholen, Frank, Higano, Celestia S., Shore, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184267/
https://www.ncbi.nlm.nih.gov/pubmed/35190653
http://dx.doi.org/10.1038/s41391-021-00488-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184267/
https://www.ncbi.nlm.nih.gov/pubmed/35190653
http://dx.doi.org/10.1038/s41391-021-00488-0

Ejemplares similares